Comparative Pharmacology
Head-to-head clinical analysis: TICLID versus ZONTIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TICLID versus ZONTIVITY.
TICLID vs ZONTIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
ZONTIVITY (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. It does not directly inhibit thrombin activity but blocks thrombin-mediated platelet activation.
250 mg orally twice daily
1 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment.
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Primarily as unchanged drug via renal excretion (approximately 80%) and fecal/biliary elimination (approximately 20%).
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent